IL31 Rabbit Polyclonal Antibody
IL31 rabbit polyclonal antibody, Aff - Purified
|Recommended Dilution||Indirect ELISA: To detect Human IL-31 (using 100 μl/well antibody solution) a concentration of 0.5-2.0 μg/ml of this antibody is required. In conjunction with compatible secondary reagents, it allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-31.
Sandwich ELISA: To detect Human IL-31 (using 100 μl/well antibody solution) a concentration of 0.5-2.0 μg/ml of this antibody is required. In conjunction with Biotinylated Anti-Human IL-31 (Cat.-No. AP01149BT)as a detection antibody, it allows the detection of at least 0.2-0.4 ng/well of recombinant Human IL-31.
Western blot: To detect Human IL-31 this antibody can be used at a concentration of 0.1-0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-31 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
|Immunogen||Highly pure (> 98%) E.coli derived recombinant Human IL-31|
|Specificity||This antibody detects Human Interleukin-31.|
|Formulation||PBS, pH 7.2
State: Aff - Purified
State: Lyophilized (sterile filtered) purified Ig fraction
|Reconstitution Method||Restore in sterile water to a concentration of 0.1-1.0 mg/ml.|
|Background||Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.|
|Note||Centrifuge vial prior to opening.|